1. Home
  2. HOOK vs IINN Comparison

HOOK vs IINN Comparison

Compare HOOK & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOOK
  • IINN
  • Stock Information
  • Founded
  • HOOK 2011
  • IINN 2018
  • Country
  • HOOK United States
  • IINN Israel
  • Employees
  • HOOK N/A
  • IINN N/A
  • Industry
  • HOOK Biotechnology: Pharmaceutical Preparations
  • IINN Medical/Dental Instruments
  • Sector
  • HOOK Health Care
  • IINN Health Care
  • Exchange
  • HOOK Nasdaq
  • IINN Nasdaq
  • Market Cap
  • HOOK 11.9M
  • IINN 13.7M
  • IPO Year
  • HOOK 2019
  • IINN 2021
  • Fundamental
  • Price
  • HOOK $0.89
  • IINN $1.23
  • Analyst Decision
  • HOOK Hold
  • IINN Strong Buy
  • Analyst Count
  • HOOK 3
  • IINN 1
  • Target Price
  • HOOK $4.50
  • IINN $2.00
  • AVG Volume (30 Days)
  • HOOK 155.2K
  • IINN 910.9K
  • Earning Date
  • HOOK 08-11-2025
  • IINN 08-14-2025
  • Dividend Yield
  • HOOK N/A
  • IINN N/A
  • EPS Growth
  • HOOK N/A
  • IINN N/A
  • EPS
  • HOOK N/A
  • IINN N/A
  • Revenue
  • HOOK $9,351,000.00
  • IINN N/A
  • Revenue This Year
  • HOOK N/A
  • IINN N/A
  • Revenue Next Year
  • HOOK N/A
  • IINN $200.00
  • P/E Ratio
  • HOOK N/A
  • IINN N/A
  • Revenue Growth
  • HOOK N/A
  • IINN N/A
  • 52 Week Low
  • HOOK $0.72
  • IINN $0.40
  • 52 Week High
  • HOOK $6.00
  • IINN $1.65
  • Technical
  • Relative Strength Index (RSI)
  • HOOK 19.78
  • IINN 50.88
  • Support Level
  • HOOK $0.89
  • IINN $1.22
  • Resistance Level
  • HOOK $0.95
  • IINN $1.33
  • Average True Range (ATR)
  • HOOK 0.06
  • IINN 0.12
  • MACD
  • HOOK -0.01
  • IINN -0.04
  • Stochastic Oscillator
  • HOOK 7.11
  • IINN 8.57

About HOOK HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

About IINN Inspira Technologies Oxy B.H.N. Ltd.

Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Share on Social Networks: